Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
McGill University
$120,000.00
Allosteric TNAP activation for bone and fat cell health: from basic mechanism to therapeutic development.
EF 2025-26
Résumé
Tissue non-specific alkaline phosphatase (TNAP) is an enzyme that helps control both bone formation and how our bodies use energy. In bone-forming cells (osteoblasts), TNAP breaks down a compound called pyrophosphate (PPi) into phosphate (Pi), which is essential to build strong bones. Insufficient TNAP activity can cause hypophosphatasia, a genetic disease that weakens bone and cartilage.
TNAP also plays a key role in a special type of fat called brown fat. Unlike regular fat, brown fat burns calories to make heat, which helps regulate blood sugar and overall metabolic health. Because of this, brown fat is a promising target for treating type 2 diabetes (T2D) and obesity. We have found that people with TNAP mutations often have trouble controlling blood sugar, which may increase their risk for T2D.
Currently, drugs like GLP-1 receptor agonists are used to treat obesity and diabetes, but they don't work for everyone and can have side effects. Our recent discovery shows that glycerol, a small natural molecule, can bind to TNAP and increase its activity, supporting both bone formation and energy burning in fat.
My research will build on this finding to identify stronger and more effective TNAP activators. I will test how TNAP variants found in humans affect bone health and metabolism. By studying these variants in genetically modified mice, we will learn how TNAP influences bone strength, blood sugar, and fat burning.
Current treatments for bone disorders are costly and invasive, while existing therapies for obesity do not work for everyone and can cause side effects. Developing new ways to activate TNAP could provide safer and more effective options, both for rare bone diseases like hypophosphatasia and for improving glucose control and reducing obesity. By addressing conditions that range from rare genetic disorders to widespread metabolic diseases, this work has the potential to deliver significant health benefits for people in Canada and around the world.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
560225
Name
Oppong Abel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Allosteric TNAP activation for bone and fat cell health: from basic mechanism to therapeutic development.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Adipose Tissue; Bone Mineralization; Diabetes; Hypophosphatasia; Obesity; Thermogenesis
Abstract
Tissue non-specific alkaline phosphatase (TNAP) is an enzyme that helps control both bone formation and how our bodies use energy. In bone-forming cells (osteoblasts), TNAP breaks down a compound called pyrophosphate (PPi) into phosphate (Pi), which is essential to build strong bones. Insufficient TNAP activity can cause hypophosphatasia, a genetic disease that weakens bone and cartilage.
TNAP also plays a key role in a special type of fat called brown fat. Unlike regular fat, brown fat burns calories to make heat, which helps regulate blood sugar and overall metabolic health. Because of this, brown fat is a promising target for treating type 2 diabetes (T2D) and obesity. We have found that people with TNAP mutations often have trouble controlling blood sugar, which may increase their risk for T2D.
Currently, drugs like GLP-1 receptor agonists are used to treat obesity and diabetes, but they don't work for everyone and can have side effects. Our recent discovery shows that glycerol, a small natural molecule, can bind to TNAP and increase its activity, supporting both bone formation and energy burning in fat.
My research will build on this finding to identify stronger and more effective TNAP activators. I will test how TNAP variants found in humans affect bone health and metabolism. By studying these variants in genetically modified mice, we will learn how TNAP influences bone strength, blood sugar, and fat burning.
Current treatments for bone disorders are costly and invasive, while existing therapies for obesity do not work for everyone and can cause side effects. Developing new ways to activate TNAP could provide safer and more effective options, both for rare bone diseases like hypophosphatasia and for improving glucose control and reducing obesity. By addressing conditions that range from rare genetic disorders to widespread metabolic diseases, this work has the potential to deliver significant health benefits for people in Canada and around the world.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Oppong, Abel
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~